Some of the content on this website requires JavaScript to be enabled in your web browser to function as intended. While the website is still usable without JavaScript, it should be enabled to enjoy the full interactive experience.

Skip to Main Navigation. Each navigation link will open a list of sub navigation links.

Skip to Main Content

Wyoming Drug Utilization Review (WY-DUR)|School of Pharmacy | College of Health Sciences

Contact Us

Wyoming Drug Utilization Review (WY-DUR)
Dept. 3375
1000 E. University Ave.
Laramie, WY 82070
Phone: 307-766-6750
Fax: 307-766-2953


The Wyoming Department of Health is conducting a survey concerning the use and barriers to use of 17-alpha hydroxyprogesterone in pregnant women.  If you routinely provide prenatal care for your pregnant patients, please participate in this survey.

The Draft 2016 PDL is available for review. Please submit comments before January 1, 2016.

New Drug Review: Possible P & T Committee Decisions (May 2015)

Preferred Drug List (PDL)

The Wyoming Medicaid Preferred Drug List (PDL) including step utilization for anti-depressant medications and prior authorization information is available at the Wyoming EqualityCare Pharmacy Provider website. To view the current PDL, please visit 

Public Comment at Meetings

 A new policy for public comment at meetings is effective December 1, 2012. 

PhRMA Guidelines and PhRMA Comment Request Form (updated November 5, 2015)

Public Guidelines and Public Comment Request Form (updated November 5, 2015)

Proposed Criteria

The following prior authorization criteria were approved at the May 11, 2016 P & T Committee meeting.

  • Victoza will be limited to a dose of 1.8 mg per day.  Lyrica will be limited to 600 mg per day.  Suboxone will be limited to 16 mg per day for the first two years and 8 mg per day after two years.
  • The diagnosis requirement for ADHD in children aged 4 – 17 years will be removed.  For those patients who require the diagnosis, the lookback period will be 14 months.
  • Zepatier will be allowed under current Hepatitis C clinical criteria with an additional requirement for NS5A polymorphism testing. 

Comments may be sent by email to or by mail to: Wyoming Drug Utilization Review Board, Dept. 3375, 1000 E. University Avenue, Laramie, WY   82071.   Comments should be received prior to July 1, 2016.

P & T Committee Meeting Dates

Agenda August 11, 2016

Minutes May 11, 2016

2016 Meetings

Thursday, February 11; Wednesday, May 11; Thursday, August 11; Thursday, November 10

All meetings are at 10 am at Laramie County Community College. Please see agenda for room location.

Share This Page:

Footer Navigation

University of Wyoming Medallion
1000 E. University Ave. Laramie, WY 82071 // UW Operators (307) 766-1121 // Contact Us // Download Adobe Reader // Accessibility Accessibility information icon